Phase 1 trial of mAb114 in Africa
Latest Information Update: 02 Feb 2019
At a glance
- Drugs Ansuvimab (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
Most Recent Events
- 02 Feb 2019 New trial record
- 24 Jan 2019 According to a National Institute of Allergy and Infectious Diseases Media Release, the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) is planning to conduct this trial.